Skip to main content

Table 8 Further one way and multi way sensitivity analyses

From: Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

  Benefit-cost ratio PCV13 vs. ‘PPV23 Benefit-cost ratio PCV13 vs. ‘no vaccination’
  Only direct cost Including indirect cost Only direct cost Including indirect cost
Base case 2.09 € 2.16 € 1.27 € 1.32 €
PCV13 revaccination according to current PPV23 adult vaccination recommendations in Germany [[15]] 2.97 € 3.11 € 1.08 € 1.14 €
Revaccination PCV13 not needed 16.74 € 17.26 € 2.81 € 2.92 €
Revaccination PCV13 every 5 years 0.97 € 1.00 € 0.75 € 0.78 €
Incidence for in- and outpatient CAP according to Schnoor et al.: -55% [[48]] 1.01 € 1.05 € 0.65 € 0.68 €
PPV23 effectiveness against IPD upper limit [[9]] 2.07 € 2.14 € 1.27 € 1.32 €
PPV23 effectiveness against IPD lower limit [[9]] 2.12 € 2.19 € 1.27 € 1.32 €
PPV23 effective in preventing inpatient CAP according to Maruyama et al. [[29]]: 45% 0.86 € 0.88 € 1.28 € 1.34 €
PCV13 ineffective in preventing in- and outpatient CAP 0.17 € 0.17 € 0.16 € 0.18 €
No indirect herd effects of PCV7 vaccination 2.51 € 2.60 € 1.54 € 1.61 €